Next Article in Journal / Special Issue
iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development
Previous Article in Journal
Neurosurgical Hyponatremia
Previous Article in Special Issue
Human iPS Cell-Derived Germ Cells: Current Status and Clinical Potential
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2014, 3(4), 1105-1123; doi:10.3390/jcm3041105

Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells

1,2
,
1,2
and
1,2,3,4,*
1
Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China
2
Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China
3
Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine, the University of Hong Kong and Guangzhou Institutes of Biomedicine and Health, Hong Kong SAR, China
4
Shenzhen Institutes of Research and Innovation, the University of Hong Kong, Hong Kong SAR, China
*
Author to whom correspondence should be addressed.
Received: 31 July 2014 / Revised: 15 September 2014 / Accepted: 17 September 2014 / Published: 15 October 2014
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [972 KB, uploaded 15 October 2014]   |  

Abstract

The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail. View Full-Text
Keywords: patient-specific-iPSCs-derived cardiomyocytes; regenerative medicine; modeling of inherited cardiac disorder; drug testing; toxicology studies patient-specific-iPSCs-derived cardiomyocytes; regenerative medicine; modeling of inherited cardiac disorder; drug testing; toxicology studies
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ng, K.-M.; Law, C.-Y.; Tse, H.-F. Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells. J. Clin. Med. 2014, 3, 1105-1123.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top